Defective complement regulation results in hemolytic uremic syndrome (HUS), a disease that is characterized by microangiopathy, thrombocytopenia, and acute renal failure and that causes endothelial cell damage. For characterization of how defective complement regulation relates to the pathophysiology, the role of the complement regulator factor H and also of a mutant factor H protein was studied on the surface of human umbilical vein endothelial cells. The mutant 145-kD factor H protein was purified to homogeneity, from plasma of a patient with HUS, who is heterozygous for a factor H gene mutation G3587T, which introduces a stop codon at position 1172. Functional analyses show that the lack of the most C-terminal domain short consensus repeats 20 severely affected recognition functions (i.e., binding to heparin, C3b, C3d, and the surface of endothelial cells). Wild-type factor H as well as the mutant protein formed dimers in solution as shown by cross-linking studies and mass spectroscopy. When assayed in fluid phase, the complement regulatory activity of the mutant protein was normal and comparable to wild-type factor H. However, on the surface of endothelial cells, the mutant factor H protein showed severely reduced regulatory activities and lacked protective functions. Similarly, with the use of sheep erythrocytes, the mutant protein lacked the protective activity and caused increased hemolysis when it was added to factor H-depleted plasma. This study shows how a mutation that affects the C-terminal region of the factor H protein leads to defective complement control on cell surfaces and damage to endothelial cells in patients with HUS. These effects explain how mutant factor H causes defective complement control and in HUS-particularly under condition of inflammation and complement activation-causes endothelial cell damage.
H emolytic uremic syndrome (HUS) is a disease that is characterized by microangiopathy, thrombocytopenia, and acute renal failure (1) . The disease is divided into a diarrhea-associated form (D ϩ HUS) that occurs in children and a non-diarrhea-associated form that occurs predominantly in adults (D Ϫ HUS). The D ϩ form is caused mostly by entero hemorrhagic Escherichia coli or shigella and is triggered by a toxin (e.g., shiga toxin, shiga toxin-like products) that is released by the pathogens. The disease causes renal defects. Usually, patients with D ϩ HUS have a good prognosis; most recover, and renal function returns to normal (2) . The atypical form of HUS is free of entero hemorrhagic Escherichia coli infections, occurs in children and adults, and can be sporadic or familial. Defective complement control is evidenced by low C3 and normal C4 serum levels in serum. Deregulation of alternative pathway activation is shown by low APH50 values and the appearance of C3 degradation products. Patients with D Ϫ HUS have a poor prognosis, and the disease usually progresses to end-stage renal failure. Genetic analysis of patients with D Ϫ HUS has identified mutations of genes that code for individual complement regulators, such as the soluble regulators factor H and factor I and the membrane-bound regulator membrane cofactor protein (MCP) (CD46) (3) (4) (5) (6) (7) (8) (9) . In addition, autoantibodies against the soluble regulator factor H were reported in three patients with HUS (10) . These regulatory proteins have in common that they control the activity and the stability of the alternative pathway amplification convertase C3bBb (11) . Factor H is a central human regulator that controls complement activation at the level of C3b (12) (13) (14) (15) (16) (17) . The secreted 150-kD factor H glycoprotein is composed exclusively of individually folding domains, which are termed short consensus repeats (SCR) or complement control protein module (18, 19) . Factor H gene mutations have been observed in approximately 20% of patients with HUS (20, 21) . So far, more than 70 patients with mutations in the factor H gene have been published. The vast majority of the reported factor H gene mutations are heterozy-gous; therefore, patients have one intact and one defective allele (for review, see reference [22] ). The C-terminus of factor H represents a hotspot for mutations. A total of 70% of all mutations are located in domains 19 and 20 of the factor H gene and represent either premature stop codons or single amino acid substitutions. The C-terminus includes the recognition region and has binding sites for ligands such as heparin, C3b, and C3d and to the surface of endothelial cells.
Given the association of factor H gene mutations in HUS, it is of interest to elucidate how C-terminal recognition domain relates to the pathomechanism of HUS and endothelial cell damage. Here, we show for the first time, to our knowledge, that factor H mediates its protective, inhibitory activity at the surface of endothelial cells. In addition, we show that a mutant factor H protein, which has the C-terminal domain SCR20 deleted and was purified from serum of a patient with HUS, displays defective recognition and regulatory functions at the surface of endothelial cells and sheep erythrocytes but shows normal regulatory activity in the fluid phase (i.e., plasma). Therefore, modifications of the C-terminal recognition regions of factor H impair the regulatory functions on the surface of endothelial cells.
Materials and Methods

The Patient
The patient R043 is heterozygous for a mutation in the factor H gene nucleotide position G3587T within domain 20, introducing a stop codon at position 1172. The patient tested negative for C3 nephritic factor. All experiments were conducted with the patient's informed consent. Hemolysis and renal function ameliorated after an intense course of plasma exchanges; however, in the subsequent 2 yr, the patient manifested three HUS recurrences. A renal biopsy that was performed in February 1997 showed irreversible changes of chronic nephropathy with severe thrombotic microangiopathy. Renal function rapidly worsened, and in 1998, the patient started hemodialysis. In 1999, he received a cadaveric kidney transplant, but the graft failed within 1 mo because of disease recurrence. The factor H concentration in the plasma of this patient was elevated (908 g/ml; normal range 350 to 800 g/ml), and C3 plasma levels were reduced (0.51 mg/ml; normal range 0.81 to 1.70 mg/ml).
Purification of Mutant Factor H
Approximately 10 ml of serum from patient R043 was treated with 13% polyethylene glycol (molecular weight 6000 Da) on ice. The pellet was dissolved in 1 ml of buffer A (10 mmol/L sodium phosphate and 100 mmol/L glycine [pH 7.3]) and applied to heparin affinity chromatography (HiTrap Heparin column; GE Health Care, Freiburg, Germany). After extensive washing with buffer A, proteins were eluted with a linear salt gradient (30 to 500 mmol/L NaCl). Fractions of 400 l were collected, and factor H-containing fractions were combined, diluted with deionized water, and subjected to ion exchange chromatography (Resource Q column; GE Health Care) using buffer A. Again, bound proteins were eluted with a linear salt gradient (range 30 to 600 mmol/L NaCl), and factor H-containing fractions were combined and concentrated. The factor H concentration was determined by ELISA (23) .
Surface Plasmon Resonance Binding
Protein-protein interactions were analyzed by surface plasmon resonance using a BIAcore 3000 system (BIAcore AB, Uppsala, Sweden) as described previously (24) .
Cultivation of Endothelial Cells and Binding Experiments
Human umbilical vein endothelial cells (HUVEC; American Type Culture Collection, Rockville, MD) express the membrane-bound regulators MCP (CD46), decay-accelerating factor (DAF) (CD55), and CD59 but not complement receptor 1 (CR1) (CD35) and were cultured as described previously (24) . Binding experiments with flow cytometry and confocal microscopy were performed as described previously (25) .
Co-Factor Activity
Co-factor assays for fluid phase activity were performed as described previously (26) . For determination of co-factor activity on the surface, HUVEC were cultivated in serum-free medium, washed thoroughly, and detached from the surface. Cells were incubated with purified truncated mutant factor H (factor H ⌬20 ) or wild-type factor H (factor H wt ; 2 g) for 1 h at 37°C under gentle agitation. Then cells were washed three times with cold Dulbecco's phosphate-buffered saline and incubated at 37°C in the presence of 120 ng of C3b (Merck Biosciences, Schwalbach, Germany) and 240 ng of factor I (Merck Biosciences). At each time point, 2 ϫ 10 5 cells were sedimented, the supernatant was transferred to sample buffer and separated by SDS-PAGE, and C3b degradation fragments were detected by Western blotting.
Depletion of Factor H of Plasma
Factor H-depleted human plasma was prepared using immune affinity column as described previously (27) . Successful depletion was determined by Western blotting, and complement activity was confirmed by assay of lysis of sheep erythrocytes.
Hemolysis Assay
Hemolytic experiments were conducted in the presence of veronal buffered saline (144 mmol/L NaCl, 7 mmol/L MgCl 2 , and 10 mmol/L EGTA [pH 7.4]). Increasing amounts of purified factor H wt or factor H ⌬20 were added to the depleted plasma together with 2 ϫ 10 7 sheep erythrocytes. The mixture was treated for 30 min at 37°C. After centrifugation, hemolysis was determined by measurement of the absorbance at 414 nm.
Cross-Linking
The homobifunctional cross-linker dimethyladipimidate-dihydrochloride (DMA) was used (Pierce Perbio Science, Bonn, Germany). Purified protein (1 g) or human plasma (1 l) was treated in crosslinking buffer (200 mmol/L triethanolamine [pH 9.0]) in the presence of 1 mmol/L DMA. The mixture was incubated at 25°C for 60 min in the dark. Reactions were stopped by addition of 10 l of 1 mol/L Tris buffer (pH 9.0).
SDS-PAGE and Western Blotting
Human serum, individual chromatography fractions, cell supernatants, and cell lysates were separated by 10% SDS-PAGE under nonreducing conditions (28) .
Mass Spectroscopy
The PepClean C18 Spin columns kit (Pierce Perbio Science) was used to remove the contaminants from the PBS buffer in which the purified proteins were stored. The samples were mixed 1:1 with saturated sinapinic acid (sinapinic acid in 0.1% [vol/vol], trifluoracetic acid, and H 2 O [2:1]). Part of the sample (1 to 3 l, depending on the protein concentration) was transferred onto the target (MTP384 ground steel; Bruker Daltonics, Bremen, Germany). Samples were let dry at room temperature (dried droplet procedure). The measurements were conducted with an Ultraflex TOF/TOF (Bruker Daltonics).
Results
Identification of a Mutated Factor H Protein in the Plasma of Patient R043
Patient R043 is heterozygous for a nonsense factor H gene mutation at nucleotide position G3587T. This mutation introduces in SCR20 at position 1172, a premature stop codon. Consequently, the mutant factor H ⌬20 protein has most of SCR20 deleted. Plasma of this patient was separated by SDS-PAGE and subjected to Western blot analysis. Two bands of 150 and 145 kD were identified, representing factor H wt and factor H ⌬20 ( Figure 1A , top, lane 2). Both the 150-and 145-kD bands have similar intensities, indicating that the wild-type and mutant proteins are expressed in equal levels. Absence of the most C-terminal SCR domain in factor H ⌬20 was confirmed with an epitope-mapped mAb that binds within SCR20. This mAb D24 detected the 150-kD factor H wt but not the mutant factor H ⌬20 protein ( Figure 1A , bottom). These results show that the mutant protein is expressed, secreted, and present in plasma in a truncated form.
Purification of Factor H ⌬20 from Plasma
Heparin affinity chromatography was used to separate factor H ⌬20 and factor H wt proteins. The mutant factor H ⌬20 eluted in one peak, at a NaCl concentration of approximately 230 mM and factor H wt in a second peak at approximately 300 mM NaCl (data not shown). The individual fractions were separated by SDS-PAGE and analyzed by Western blotting. The factor H ⌬20 protein was present in fractions 18 to 26, fraction 28 contained both proteins, and factions 30 to 36 contained the factor H wt protein. Thus, factor H ⌬20 binds with reduced affinity to heparin.
Fractions that contained either factor H ⌬20 or factor H wt protein were combined, and the protein was purified to homogeneity. Purified proteins were free of contamination bands as determined by SDS-PAGE in combination with Western blotting ( Figure 1B 
Binding of Purified Mutant Factor H ⌬20 to C3b and C3d
Surface plasmon resonance was used to assay how the truncation of SCR20 affects binding to the central complement component C3b. C3b was coupled covalently to the surface of the sensor chip, and factor H ⌬20 or factor H wt was added in equal amounts to the fluid phase. Factor H ⌬20 bound weakly to immobilized C3b, as indicated by the low and weak association and dissociation profile (Figure 2) . Thus, truncation of the most C-terminal domain strongly reduced binding to C3b. In contrast, factor H wt bound with high affinity to immobilized C3b, as indicated by the strong association and dissociation profile. Similar binding profiles were observed for C3d, the cleavage product of C3b, that is recognized by the C-terminal domain 20 of factor H. In contrast to factor H wt , the mutant factor H ⌬20 did not bind to C3d (Figure 2 ). These results show that deletion of the C-terminal domain in the factor H ⌬20 protein severely affects binding to C3b and to C3d.
Binding of Purified Mutant Factor H ⌬20 to Endothelial Cells
Flow cytometry was used to assay binding of purified factor H ⌬20 or factor H wt to HUVEC. Mutant factor H ⌬20 bound weakly to HUVEC (mean fluorescence 4.1), and factor H wt was stronger (mean fluorescence 77.0; data not shown). A polyclonal factor H antiserum that identifies multiple domains of the protein and that stains equally well with the mutant and wild-type proteins was used. (Bottom) MAb D24 that is specific for domain 20 of factor H identified the 150-kD factor H wt but not the mutant factor H ⌬20 protein, which lacks this domain. (B) Reactivity of purified factor H ⌬20 and factor H wt . The purified mutant and wild-type proteins show reactivity with factor H antiserum, and factor H wt but not mutant factor H reacts with mAB D24. Silver staining shows that both mutant and wild-type proteins are purified to homogeneity (bottom). (C) Domain structure of factor H indicating the 20 short consensus repeats (SCR; or CCP modules) of the intact protein. The most C-terminal domain SCR20 is absent in the mutant factor H ⌬20 protein and is shown by a dotted line. The binding epitope of mAB D24 is indicated, the N-terminal complement regulatory region that is contained in domains SCR1 through SCR4, and the C-terminal recognition region SCR19 and SCR20 are indicated by bars.
Confocal Microscopy
In addition, surface attachment of factor H was visualized by confocal microscopy. Binding of either mutant factor H ⌬20 or factor H wt was detected with an antiserum that resulted in green fluorescence. Factor H ⌬20 bound weakly and factor H wt strongly to the endothelial cell surface. Nuclei were stained with DAPI (blue color) and cell surfaces with Alexa 633-conjugated wheat germ agglutinin (red color). Upon merging of the channels, the yellow signal reveals surface localization of factor H ( Figure 3A) . Thus, three approaches, confocal microscopy, flow cytometry, and a biochemical assay, show reduced cell binding of mutant factor H ⌬20 and strong binding of factor H wt . This identifies SCR20 as the major cell attachment domain of factor H.
Assaying Cell Surface-Bound Proteins by Western Blotting
Binding of factor H ⌬20 or factor H wt to endothelial cell surface was examined further with a biochemical method. After incubation with purified proteins, cells were lysed and surfaceattached proteins were assayed by Western blotting after SDS-PAGE separation. Reduced binding of the mutant factor H ⌬20 to the cell surface as compared with factor H wt is indicated by the different intensities of the bands ( Figure 3B, lanes 2 and 3) . Cells that were treated in medium alone showed no surfaceattached factor H ( Figure 3B, lane 1) .
Binding of Serum-Derived Factor H of Patient R043 to Endothelial Cells
Patient R043 is heterozygous for the E1172Stop mutation; therefore, in plasma, both mutant factor H ⌬20 and factor H wt are present ( Figure 1A, top, lane 2) . When serum of patient R043 and that of a healthy control subject were used for cell binding, a dosage-dependent binding of factor H to HUVEC was observed. In the patient's serum, binding was weaker than with the control serum. A direct comparison of the median fluorescence confirmed the reduced binding of the patient's plasma ( Figure 3C) .
Dimerization of Factor H
The reduced binding profile that was observed with plasma of the heterozygous patient suggested an interaction of mutant factor H ⌬20 and factor H wt . Therefore, dimer formation was tested by chemical cross-linking. First purified factor H wt was treated with the cross-linker DMA and analyzed by SDS-PAGE together with Western blotting. This approach identified two prominent bands of 150 and 300 kD, representing the monomeric form and a dimeric complex (Figure 4, lane 2) . Upon treatment of human plasma, the same monomeric and dimeric complexes were identified (Figure 4, lanes 4 and 5) . However, when plasma of patient R043 was treated, the pattern was more complex. In addition to the monomeric 145-and 150-kD bands, representing mutant factor H ⌬20 and factor H wt , additional bands of approximately 290 and 300 kD were detected ( Figure  4 , lanes 7 and 8). This pattern suggests dimer formation of both the mutant factor H ⌬20 and factor H wt proteins. On the basis of the intensity of the 145-kD mutant and the 150-kD wild-type bands, it seems that the wild-type protein forms dimers more easily. Matrix-assisted laser desorption ionization-time of flight analysis yielded for the purified factor H wt and factor H ⌬20 monomer masses of 151,126.617 and 145,116.287 Da. The masses of the dimeric forms of factor H wt and factor H ⌬20 were 301,065.401 and 290,979.657 Da, respectively.
Co-Factor Activity of factor H ⌬20 and factor H wt
To assay how the factor H mutation relates to disease, we compared the regulatory activity of the factor H ⌬20 and factor H wt proteins. In fluid phase, mutant factor H ⌬20 and factor H wt showed comparable co-factor activity as evidenced by the appearance and the intensity of the ␣Ј46-and ␣Ј43-kD bands of C3b ( Figure 5A , factor H wt versus factor H ⌬20 ). C3b cleavage products were detected already after 20 s, and their intensity increased with time. Thus, in fluid phase, the mutant factor H ⌬20 and factor H wt proteins have comparable regulatory activities, and SCR20 is dispensable for this activity.
Co-Factor Activity on the Cell Surface
HUS is associated with endothelial cell damage. To link defective cell binding with surface control, we analyzed cofactor activity of factor H directly on the cell surface.
The endothelial cells that were used here express MCP (CD46), DAF (CD55), and CD59 but not CR1 (CD35; data not shown). First, the endogenous co-factor activity of the integral membrane complement regulators was assayed. Endothelial cells were incubated with C3b and factor I, and C3b degradation was followed upon separation of the cell lysate by SDS-PAGE in combination with Western blotting. Degradation products in the form of ␣Ј68-, ␣Ј46-, and ␣Ј43-kD fragments of the C3b ␣Ј chain were detectable after 45 min, and their intensity increased with time ( Figure 5B, top) . Therefore, the endog- Figure 2 . Reduced binding of mutant factor H ⌬20 to the central complement component C3b and C3d. Binding of purified mutant factor H ⌬20 and factor H wt to immobilized C3b and C3d was analyzed by surface plasmon resonance. Factor H ⌬20 bound weakly to C3b and showed low binding to C3d. Binding of factor H wt to both C3b and C3d is indicated by the strong association and dissociation profiles. Mutant factor H ⌬20 or factor H wt was injected into a flow cell or into a control flow cell. The profile that was obtained in the control flow cell was subtracted.
enous, integral membrane regulators MCP and DAF control C3 activation at the surface of HUVEC.
To demonstrate a role of surface-attached factor H, we incubated HUVEC with factor H wt . In the presence of factor H wt , degradation products were detected earlier, already after 2.5 min, and after 120 min, their intensity was prominent, thereby demonstrating that factor H displays co-factor activity on the cell surface and that a combination of endogenous and attached complement regulators controls C3b on the cell surface. On the basis of the intensities of the cleavage products of factor H-treated versus untreated cells, factor H wt enhances the regulatory activity approximately 10-fold. Therefore, surface-attached factor H contributes to C3b inactivation and mediates complement control ( Figure 5B, middle) .
Having demonstrated a regulatory role of factor H on the surface, we assayed the mutant protein. Mutant factor H ⌬20 protein showed a reduced regulatory activity; cleavage products were identified after 35 and 45 min ( Figure 5B, bottom) . The protective activity of the mutant protein was lower than that of the wild-type protein. A densitometric analysis of the ␣Ј46-kD band showed that the activity of the mutant protein is approximately one third that of the wild-type protein.
Hemolysis of Sheep Erythrocytes
In addition, a hemolysis assay with factor H-depleted plasma was used to analyze how the E1172Stop mutation affects the protective function of the protein. Sheep erythrocytes were incubated in factor H-depleted human plasma, and increasing amounts of either purified factor H wt or factor H ⌬20 were added. Factor H wt has a protective effect, as demonstrated by the concentration-dependent decrease of hemolysis ( Figure  6 ). In contrast, addition of the same concentrations of factor H ⌬20 resulted in an increase in lysis; no protective effect was observed ( Figure 6 ). Therefore, the loss of SCR20 in mutant factor H ⌬20 results in a reduction of the protective activity on sheep erythrocytes from complement-mediated lysis.
Discussion
Factor H gene mutations are associated with HUS; however, it is unclear how exactly such mutations cause endothelial cell HUVEC that were kept in serum-free medium for 24 h were incubated with 20 g of purified factor H ⌬20 or factor H wt for 2 h. After extensive washing, cells were treated first with a polyclonal factor H antiserum and a secondary Alexa 488 -labeled anti-rabbit antibody antiserum (green), in combination with DAPI (blue: nuclear staining) and Texas red for identification of cellular membranes. (B) Binding of mutant factor H ⌬20 and factor H wt to HUVEC as analyzed by Western blotting. Cells that were incubated for 1 h with the purified proteins were washed thoroughly and lysed. The cell lysate was separated by SDS-PAGE and transferred to a membrane, and factor H was identified by Western blotting. (C) Binding of factor H to endothelial cells using serial dilutions of plasma that was derived from patient R043, which contains mutant factor H ⌬20 and factor H wt . Dosage-dependent binding was analyzed by flow cytometry. Mean fluorescence values that were obtained for the various serum dilutions are shown. f, plasma of the control individual; ࡗ, plasma of patient R043.
damage. Here, we demonstrate for a mutant factor H protein that was derived from a patient with HUS severely reduced regulatory activity on the cell surface. The mutant factor H protein was purified from plasma of a heterozygous patient with HUS, with a G3587T exchange, that introduces a premature stop codon at position 1172. The mutant 145-kD factor H ⌬20 protein shows defective binding to heparin, to C3b, to C3d, and to the surface of endothelial cells. The complement regulatory activity of the mutant protein was comparable to factor H wt in fluid phase but was strongly reduced on the cell surfaces (HUVEC and sheep erythrocytes). These results demonstrate a protective role of the plasma regulator factor H for complement control on the surface of endothelial cells and erythrocytes.
Factor H is the central fluid-phase complement regulator and, as shown here, also regulates complement activation on the surface of endothelial cells and erythrocytes. The mutant factor H ⌬20 protein shows defective recognition functions (reduced binding to C3b, C3d, heparin, and endothelial cells; Figures 2 and 3) . Defective cell binding of factor H was observed both with purified mutant protein and with plasma of the heterozygous patient. In the patient's plasma, which contains a mixture of mutant factor H ⌬20 and factor H wt , factor H levels were increased (908 g/ml factor H), and both proteins are present at very similar levels (Figure 1 , top, lane 2). The reduced cell binding that was observed with patient plasma suggests an interaction of the mutant factor H ⌬20 and factor H wt proteins, which, however, seems to affect the function of intact factor H wt ( Figure 3C ). Factor H dimerization adds a new facet to the pathomechanism of HUS in heterozygous patients.
With a cross-linking approach, dimer formation was demonstrated for both factor H wt and factor H ⌬20 . Factor H dimerization was reported earlier, and recently the C-terminus was suggested as the domain that mediates dimer formation (29, 30) . The 290-kD band that was observed in the patient's plasma after cross-linking shows that the mutant protein, which lacks domain 20, forms dimers. Oligomer formation under native conditions was confirmed further by size exclusion chromatography and by mass spectrometry (data not shown).
When assayed in fluid phase, the complement regulatory activity of mutant factor H was normal and comparable to the wild-type protein. We recently proposed a conformational model for native factor H. In this model, factor H forms an omega-type structure and has the C-terminal binding sites accessible, which then form the first and initial contact with surface-bound C3b and heparin (31) . This model explains the reduced C3b binding that was observed in surface plasmon resonance (Figure 2 ) and the reduced regulatory activity, as demonstrated by Figure 4B . Upon surface contact, the condensed factor H molecule unfolds and has the additional binding sites accessible. Apparently the recognition domain 20 of factor H, which makes the first and initial contact, includes a C3b-and heparin-binding site (32) . In fluid phase, interaction of factor H with C3b seems to be different from the interaction with surface-bound C3b and is explained by the greater flexibility of the two proteins in solution or different conformations of C3b. In the hemolysis assay, factor H wt but not factor H ⌬20 showed a dosagedependent, protective activity ( Figure 6 ).
Endothelial cells that were used in this study bind plasma regulators to their surface and express endogenous membranebound complement regulators such as MCP, DAF, and CD59 but not CR1 (data not shown). The integral membrane regulators mediate complement control at the cell surface and inactivates C3b as evidenced by the appearance of the ␣Ј46 and ␣Ј43-kD fragments ( Figure 5B, top) . Here, we demonstrate that attached factor H contributes to the protective activity and cooperates together with the membrane-bound regulators. Under the experimental conditions used here, the regulatory activity of surfaceattached factor H was pronounced and increased degradation of C3b approximately 10-fold. This finding is consistent with previous reports (31) (32) (33) (34) . However, the mutant factor H protein showed reduced regulatory activity. During a local inflammatory response, when complement is activated, endothelial cells require maximum protection. In this situation, a reduction of factor H attachment to cell surfaces and regulatory activity causes inefficient complement control and leads to cell damage. The defective complement control described here for a mutant factor H protein that lacks the recognition module, has implications for the other Figure 4 . Dimerization of factor Hwt and mutant factor H ⌬20 . Purified factor H wt , serum-derived from a healthy person or patient R043, was treated with the indicated concentration of the cross-linker dimethyladipimidate-dihydrochloride. After incubation, the mixture was separated by SDS-PAGE, transferred to a membrane, and analyzed by Western blotting.
C-terminal factor H mutations that frequently are observed in HUS. It is likely that all mutations in SCR19 and 20 show a defective recognition function.
Atypical HUS is associated with endothelial cell damage and defective complement control as evidenced by low C3 plasma levels and increased levels of C3b degradation products. Apparently, the alternative pathway amplification convertase C3bBb is essential for this reaction. Consequently, a defective regulation of this enzyme, by increasing either its stability or its activity, enhances complement activation and results in tissue damage and HUS. This explains why in HUS, mutations of several complement regulators occur (e.g., factor H, MCP [CD46], factor I) and why autoantibodies to factor H have the same effect (5-10). So far, more than 75 patients with factor H gene defects have been reported, and the vast majority (75%) of the mutations are clustered in the C-terminus (SCR19 and 20) and make the C-terminal recognition domain a hotspot for disease-associated mutations in HUS. Although the initial trigger of HUS that causes endothelial cell damage still is unclear, the pathomechanism of the disease-how endothelial cells are damaged as a result of improper control of the alternative pathway convertase C3bBb-becomes evident. Figure 5 . Co-factor activity of purified factor H wt and mutant factor H ⌬20 . (A) Fluid phase. (Top) Co-factor activity of purified factor H wt was assayed in fluid phase. C3b was incubated with factor I, and factor H wt was added. Aliquots were removed at the indicated time points, inactivated, separated by SDS-PAGE, and transferred to a membrane, and the appearance of C3 fragments was analyzed by Western blotting. Co-factor activity is evidenced by disappearance of the ␣Ј chain and the appearance of the cleavage products of ␣Ј68-and ␣Ј43-kD (arrows). (Bottom) Co-factor activity of purified mutant factor H ⌬20 in fluid phase. (B) Co-factor activity on the surface of endothelial cells. (Top) Endogenous co-factor activity on HUVEC in the absence of factor H. Cells were incubated with C3b and factor I at 37°C and, at the indicated time points, inactivated, separated by SDS-PAGE, and transferred to a membrane, and the appearance of C3 fragments was analyzed by Western blotting. (Middle) Co-factor activity of purified factor H wt on endothelial HUVEC. Cells were incubated with C3b, factor I, and purified factor H wt and analyzed in the same manner. (Bottom) Co-factor activity of purified mutant factor H ⌬20 on the surface of endothelial cells. HUVEC were incubated with C3b and factor I, and mutant factor H ⌬20 was added as a co-factor. Figure 6 . Lysis of sheep erythrocytes. Sheep erythrocytes were incubated with factor H-depleted human plasma. Increasing concentrations of purified factor H wt or factor H ⌬20 were added. Erythrocyte lysis was measured by determination of the absorbance of released hemoglobin at 414 nm.
